First Presentation of HBV RNA Reduction Data, a Distinguishing Feature of Core Inhibitors SAN FRANCISCO , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and
ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Data Continues to be Anticipated in 1H 2019 ABI-H2158 Phase 1a Study Initiated ABI-H3733 Nominated as Third Core Inhibitor Candidate SAN FRANCISCO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc.
SAN FRANCISCO , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced participation at various upcoming
SAN FRANCISCO , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that the company will have an oral
SAN FRANCISCO , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), today announced that the company will be participating in the following upcoming investor conferences in September: Baird Global Healthcare Conference : Uri Lopatin , MD, Chief Medical Officer, will
- ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Initial Data Continues to be Anticipated in H1 2019 - Strong Balance Sheet Provides Significant Runway SAN FRANCISCO and INDIANAPOLIS , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc.
INDIANAPOLIS and SAN FRANCISCO, July 25, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences , Inc. (NASDAQ:ASMB) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation to ABI-H0731 for the treatment of patients with chronic Hepatitis B infection.
INDIANAPOLIS and SAN FRANCISCO , July 16, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock to the public at $36.00 per share, which included
INDIANAPOLIS and SAN FRANCISCO , July 11, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock to the public at $36.00 per share.
INDIANAPOLIS and SAN FRANCISCO , July 10, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced that it intends to offer and sell, subject to market and other conditions, 3,000,000 shares of its common stock in an underwritten public offering.
